Clinical trial NCT04851613: Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer
Official title: A Phase Ib/III Study to Evaluate the Efficacy and Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer Who Failed Standard of Care Therapies
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Breast Cancer
Lead sponsor: Laekna Limited
Sponsor class: INDUSTRY
First posted: 2021-04-20
Enrollment: 256
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Phase I: Single-arm, open-label study to evaluate efficacy, safety, tolerability, PK of the therapy with afuresertib plus fulvestrant. Phase III: A multi-center, randomized, double-blind, placebo-controlled study to assess efficacy and safety of afuresertib/placebo plus fulvestrant in patients with HR+/HER2- locally advanced or metastatic BC who have failed 1 to 2 prior lines of ET with/without a CDK4/6 inhibitor (up to 1 therapy), or chemotherapy (up to 1 chemotherapy).
Primary purpose: TREATMENT

Brief summary: Study LAE205INT3101 is a Phase Ib/III study to evaluate the efficacy and safety of the combination therapy with afuresertib plus fulvestrant (afuresertib/placebo plus fulvestrant in Phase III) in patients with HR+/HER2- breast cancer who have failed 1 to 2 prior lines of endocrine therapy, and/or CDK4/6 inhibitor (up to 1 therapy), and/or chemotherapy (up to 1 chemotherapy) as described in the inclusion criteria.

Detailed description: Eligible patients for this study must have either (1) progressive disease whilst receiving an endocrine therapy (AI or a SERM), and/or a CDK4/6 inhibitor for locally advanced or metastatic disease; or (2) relapsed with metastatic disease whilst receiving an ET (AI or SERM), and/or a CDK4/6 inhibitor, and/or chemotherapy in adjuvant setting. No more than 2 prior lines of systemic treatments for locally advanced or metastatic disease are allowed for this study, including 1-2 prior lines of endocrine therapy, with/without CDK4/6 inhibitor (up to 1 therapy), and/or chemotherapy (up to 1 therapy).

Eligibility criteria: Inclusion Criteria:

1. Female or male patients must be ≥ 18 years of age on the day of signing the informed consent and be able to provide written informed consent for the study.
2. Patients with histologically or cytologically confirmed HR+/HER2- BC characterized by the absence of HER2 expression and the presence of ER and/or PR expression.
3. HR+/HER2- BC patients must meet all the following criteria to join this study:

   1. Relapsed locally advanced (LABC) or metastatic (mBC) disease; AND
   2. Have received 1 to 2 prior lines of systemic treatments for LABC or mBC(at least one line was ET).
4. For phase Ib part, patients must have at least one lesion that meets the definition of measurable disease by RECIST 1.1 criteria; for phase III, have measurable disease and/or at least 1 lytic or mixed (lytic + sclerotic) bone lesion that can be assessed by CT or MRI; patients with sclerotic/osteoblastic bone lesions only in the absence of measurable disease are not eligible.
5. In the Phase Ib part, Patients must provide informed consent for the procedures and the tests for PIK3CA/AKT/PTEN alterations and ESR1 mutations. The biomarkers will be tested retrospectively by gene sequencing tests using archival tumor sample (preferably within 18 months/78 weeks) or from peripheral blood or from a tumor biopsy sample. Formalin-fixed, paraffin embedded (FFPE) tissue blocksare preferred. In phase III, blood sample is mandatory for this test.
6. In Phase III, subjects need to provide blood sample during the screening period for PIK3CA/AKT1/PTEN test, which will be conducted in the central laboratory. Only patients with PIK3CA/AKT1/PTEN alterations could include.
7. Patients with an Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1.
8. Patients who have adequate organ function
9. Female patients of childbearing potential must have a negative pretreatment serum pregnancy test.
10. Female patients of childbearing potential must agree to use effective contraception from enrollment to 1 year after discontinuation from the last dose of this study treatment,
11. Patients who are able to swallow and retain oral medication and without gastrointestinal diseases to interfere with drug absorption.
12. Patients must have no contraindications to fulvestrant.

Exclusion Criteria:

1. Patients who had a recent major surgery that required hospitalization for longer than 48 hours (\< 8 weeks from scheduled treatment starting date) or have used IV antibiotics for the treatment of systemic infection (\< 2 weeks from scheduled treatment starting date).
2. Patients who have additional known malignancies that are progressing or have required active treatments within 3 years of scheduled treatment starting date. (Note: Patients with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, that have undergone potentially curative therapy are not excluded).
3. Patients who have a history of seizure or conditions that may predispose them to seizure and require anti-epileptic medications, or patients who have brain arteriovenous malformation, or intracranial masses that are causing edema or clinical symptoms.
4. Patients who have known active CNS metastases and/or carcinomatous meningitis.
5. Patients who had prior treatment with fulvestrant or other selective estrogen receptor degraders (SERDs), or any PI3K/AKT/mTOR inhibitors, or any CDK4/6 inhibitors in phase I, II study.
6. Patients with QT interval corrected by the Frederica's correction formula (QTcF) \> 470 msec
7. Patients who have uncontrolled hypertension (systolic blood pressure \> 160 mmHg or diastolic blood pressure \> 100 mmHg under anti-hypertensive treatment).
8. Patients with active Hepatitis B infection \[defined as HBsAg (+) and HBV-DNA ≥ 200 IU/ml (1000 copy/ml)\] or active Hepatitis C virus \[defined as HCV antibody positive and HCV RNA (qualitative) test positive\].
9. Patients with known HIV seropositivity
10. Patients who are receiving medications that are sensitive substrates of CYP3A4, OATP1B1, or BCRP with low therapeutic index.
11. Patients who are ineligible for endocrine therapy (e.g., visceral crisis, inflammatory breast cancer).

Primary outcomes:
measure: Phase I: Overall Response Rate (ORR) based on RECIST 1.1
timeFrame: Phase I: Change from Baseline beginning at Cycle 3 Day 1 and then every 8 weeks × 40 weeks then every 3 months through study completion, an average of 1 year (each cycle is 28 days)
measure: Phase III: Progression Free Survival (PFS) based on RECIST 1.1, as assessed by investigators
timeFrame: Phase III:Change from Baseline beginning at Cycle 3 Day 1 and then every 8 weeks × 40 weeks then every 3 months through study completion, an average of 1 year (each cycle is 28 days)
Secondary outcomes:
measure: Phase I: Duration of Response (DOR) based on RECIST 1.1
timeFrame: Phase I: Change from Baseline beginning at Cycle 3 Day 1 and then every 8 weeks x 40 weeks then every 3 months through study completion, an average of 1 year (each cycle is 28 days)
measure: Phase I: Disease Control Rate (DCR) based on RECIST 1.1
timeFrame: Phase I: Change from Baseline beginning at Cycle 3 Day 1 and then every 8 weeks x 40 weeks then every 3 months through study completion, an average of 1 year (each cycle is 28 days)
measure: Phase I: Best Overall Response (BOR) based on RECIST 1.1
timeFrame: Phase I: Change from Baseline beginning at Cycle 3 Day 1 and then every 8 weeks x 40 weeks then every 3 months through study completion, an average of 1 year (each cycle is 28 days)
measure: Phase I: Progression Free Survival (PFS) based on RECIST 1.1
timeFrame: Phase I: After Cycle 3 Day 1 and then every 8 weeks x 40 weeks then every 3 months through study completion, an average of 1 year (each cycle is 28 days)
measure: Phase I: Pharmacokinetics- Time to Maximum Concentration (T-Max)
timeFrame: Phase I: Assessed on Day 1 and Day 15 of Cycle 1 (each cycle is 28 days)
measure: Phase I: Pharmacokinetics- Area Under the Curve (AUC)
timeFrame: Assessed on Day 1 and Day 15 of Cycle 1 (each cycle is 28 days)
measure: Phase I: Frequency and severity of Adverse Events (AEs)
timeFrame: Phase I: Through study completion for an average of 12 months
measure: Phase III: Progression Free Survival (PFS) based on RECIST 1.1, as assessed by BICR
timeFrame: Phase III:Change from Baseline beginning at Cycle 3 Day 1 and then every 8 weeks × 40 weeks then every 3 months through study completion, an average of 1 year (each cycle is 28 days)
measure: Phase III：Frequency and severity of Adverse Events (AEs)
timeFrame: Phase III：Through study completion
measure: Phase III：Pharmacokinetics- Time to Maximum Concentration (T-Max)
timeFrame: Assessed on Day 1 and Day 15 of Cycle 1 (each cycle is 28 days)
measure: Phase III：Pharmacokinetics- Area Under the Curve (AUC)
timeFrame: Assessed on Day 1 and Day 15 of Cycle 1 (each cycle is 28 days)
Other outcomes:
Locations:
city: Santa Monica
country: United States
facility: Providence St. Johns Health Center
state: California
city: Atlanta
country: United States
facility: Piedmont Cancer Institute
state: Georgia
city: Iowa City
country: United States
facility: University of Iowa
state: Iowa
city: Jackson
country: United States
facility: University of Mississippi Medical Center
state: Mississippi
city: Burlington
country: United States
facility: University of Vermont
state: Vermont
city: Fairfax
country: United States
facility: Virginia Cancer Specialists
state: Virginia
city: Beijing
country: China
facility: Cancer Hospital Chinese Academy of Medical Sciences
state: Beijing
Study officials:
affiliation: Laekna Limited
name: Wenyue Ma
role: STUDY_DIRECTOR
References: